Differentiated product
Eltrombopag olamine
Ready-to-use suspension · Thrombocytopenia
Product data
- Dosage form
- Ready-to-use suspension
- Dosage-form group
- Oral liquid
- Therapeutic area
- Thrombocytopenia
- Reference product
- For suspension eq. 12.5, 25 mg per sachet
- Status
- 12-month stability completed
- Development stage
- 3 of 5 · Stability data
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23